Lebrun and colleagues [15] indicated that BCAR3 acts as a putative suppressor of breast cancer progression by inhibiting the prometastatic transforming growth TGFβ/Smad signaling pathway, which helps explain the differences among studies. Here, BCAR3 is linked to breast carcinoma.